ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Scientifically-designed fasting diet lowers risks for major diseases

More evidence for calorie restriction’s longevity effect

Supplementation with vitamin D associated with improved testosterone, erectile function among middle...

A Little Zinc Goes a Long Way

Vitamin D deficiency increases risk of chronic headache

VIDEO: The Best Brain Foods That Help Increase Your Memory!

Get the Most From Your Green Tea

Iron (And More) For Lasting, Natural Energy

Metabolic syndrome increases the need for vitamin E

Supplement combo improves bone density, mood, in postmenopausal women

Print Page
Email Article

Gleevec Paired with Chemotherapy to be Further Tested in Advanced Prostate Cancer

  [ 74 votes ]   [ Discuss This Article ] • June 2, 2003

Based on results of a Phase I trial that paired Imatinib mesylate (GleevecTM) with chemotherapy to treat advanced prostate cancer, a larger Phase II/III clinical trial has just been opened at The University of Texas M. D. Anderson Cancer Center.

M. D. Anderson researchers -- the first to test Imatinib with chemotherapy -- say findings from a study of patients who already had multiple prior therapies indicate clear evidence of treatment benefit in some patients.

"There does not appear to be substantive single agent efficacy for Gleevec alone but the results in combination are provocative and have formed the basis for the randomized trial," says the study leader, Paul Mathew, M.D., assistant professor in the Department of Genitourinary Medical Oncology.

Imatinib, also known as STI 571, is the protein-tyrosine kinase inhibitor that has shown power in treating chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).

It is being studied in prostate cancer because it inhibits the platelet-derived growth factor receptor (PDGFR), the cell-division signaling pathway that is targeted by Imatinib.

PDGFR is present in the majority of prostate cancers with bone metastases and may be a valid therapeutic target.

"The pre-clinical studies conducted here at M. D. Anderson have suggested that combination therapy is necessary for effective targeting of the PDGFR," Mathew says.

The Phase I trial enrolled 28 patients whose androgen-independent prostate cancer had spread to their bones. The researchers treated the patients with Imatinib by itself for 30 days, and then added weekly injections of the chemotherapy drug docetaxel. To measure response, researchers tested the patients' prostate specific antigen (PSA) levels, a substance in the blood that indicates presence and severity of prostate cancer.

The investigators found that PSA levels continued to increase in 89 percent of patients during initial treatment with Imatinib. Measured from the start of combination therapy, 38 percent had declines in PSA more than 50 percent, 29 percent had PSA declines of up to 50 percent, and 33 percent had a rise in their PSA test.

"There was a slow and sustained drop in PSA in some patients over a long period of time when both drugs were used," says Mathew. While some of that response could be due to use of docetaxel in patients who had not been treated with that drug before, PSA levels usually drop more quickly in patients who show a response to chemotherapy, he says.

However, one patient whose bone disease had progressed on docetaxel alone, had full resolution of his bone pain and drop in his PSA with combination docetaxel and Imatinib, Mathew says.

Five out of 21 patients who completed at least six weeks of treatment had a partial response to the combination therapy, and two patients maintained their response for more than 18 months with good quality of life. Mathew adds that biopsies in two patients responding to combination therapy have demonstrated a decrease in tumor expression of PDGFR and adds "this may suggest successful targeting of PDGFR in these patients' tumors."

Apart from fatigue and nausea which responded well to dose-reductions, the treatment was generally well tolerated, Mathew says.

M. D. Anderson, Memorial Sloan-Kettering and Dana-Farber Cancer Center will enroll 144 patients in a randomized, placebo-controlled Phase II/III trial that compares treatment of Imatinib and docetaxel with docetaxel alone. Mathew adds that a cross-over provision will allow all patients on the study the opportunity to receive Imatinib.

Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® FibroSleep™ Optimized Curcumin Longvida®

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

NAD+ Ignite with Niagen

Featured Products

Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%

Natural Remedies

Sunshine Vitamin Has D-lightful Health Benefits Sunshine Vitamin Has D-lightful Health Benefits
Nutrients to Combat the Modern Stress Epidemic Nutrients to Combat the Modern Stress Epidemic
Vitamin E: Super Antioxidant We Only Thought We Knew Vitamin E: Super Antioxidant We Only Thought We Knew
The Surprising Benefits of Probiotics - What You Didn't Know The Surprising Benefits of Probiotics - What You Didn't Know
Block food Cravings At Their Molecular Root Block food Cravings At Their Molecular Root

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Get the latest news about Fibromyalgia, M.E/Chronic Fatigue Syndrome, Lyme Disease and Natural Wellness

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2017 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map